Beta-Sitosterol
CAS 83-46-5
Beta-Sitosterol (CAS 83-46-5) is a pharmaceutical compound with 7 bioactivity targets and 1 adverse event association.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 98333.33333333333 nM | 54 | - |
| - | IC50 | 40530.15411764706 nM | 16 | - |
| - | IC50 | 13.7125 ug.mL-1 | 8 | - |
| - | MIC | 41.42857142857143 ug | 7 | - |
| - | MIC | 722.6666666666666 ug.mL-1 | 3 | - |
| - | MIC | 400000 nM | 2 | - |
| - | EC50 | 19000 nM | 1 | - |
| - | Ki | 267.2 nM | 1 | - |
| Amine oxidase [flavin-containing] B Enzyme |
IC50 | 5.56 | - | Homo sapiens |
| Amine oxidase [flavin-containing] A Enzyme |
Ki | 6.34 | - | Homo sapiens |
| Prothrombin Enzyme |
Ki | 6.57 | - | Homo sapiens |
| Dipeptidyl peptidase 4 Enzyme |
IC50 | 4.54 | - | Homo sapiens |
| Nuclear factor NF-kappa-B p105 subunit Cytosolic other |
IC50 | 5.6 | - | Homo sapiens |
| Acetylcholinesterase Enzyme |
IC50 | 4.59 | - | Electrophorus electricus |
| Amine oxidase [flavin-containing] A Enzyme |
IC50 | 5.05 | - | Rattus norvegicus |
| DNA polymerase beta Enzyme |
IC50 | 4.58 | - | Homo sapiens |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Farnesoid X receptor NR1H4 |
Agonist | - | 39947414 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BETA-SITOSTEROL | 47070 | SU | MTHSPL |
| .BETA.-SITOSTEROL | 47070 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Beta-Sitosterol used for in pharmaceutical contexts?
Beta-Sitosterol (CAS 83-46-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Beta-Sitosterol?
Beta-Sitosterol has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Drug ineffective for unapproved indication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Beta-Sitosterol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Beta-Sitosterol with EU status "permitted".
What clinical phase is Beta-Sitosterol in?
No phase 1-4 clinical development badge is rendered for Beta-Sitosterol because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Beta-Sitosterol?
Beta-Sitosterol has 16 bioactivity rows in this page query. Rendered target entries include Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A, Prothrombin, Dipeptidyl peptidase 4, Nuclear factor NF-kappa-B p105 subunit.